These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2394 related items for PubMed ID: 7992096

  • 1. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC, Legha SS.
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [Abstract] [Full Text] [Related]

  • 4. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 5. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
    Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R.
    Melanoma Res; 1994 Oct 20; 4(5):327-30. PubMed ID: 7858418
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G.
    Clin Cancer Res; 2002 Sep 20; 8(9):2775-81. PubMed ID: 12231516
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F, Eggermont AM.
    Cancer J Sci Am; 1997 Dec 20; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C.
    Melanoma Res; 1993 Aug 20; 3(4):291-9. PubMed ID: 7693093
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, Italian Cooperative Oncology Group.
    Cancer; 2000 Dec 15; 89(12):2630-6. PubMed ID: 11135225
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Dec 15; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 18. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of metastasized malignant melanoma].
    Kamanabrou D.
    Praxis (Bern 1994); 2001 Mar 08; 90(10):391-6. PubMed ID: 11305184
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 120.